Chronic fatigue syndrome patients need an effective therapeutic

Ampligen, the first drug ever seeking approval to treat chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), recently hit another roadblock with the U.S. Food and Drug Administration (FDA). In its long quest to treat 1 million Americans suffering from this debilitating illness, the FDA advisory panel did not recommend the drug to be sold on the market, largely because CFS/ME doesn't have clear biomarkers such as blood tests to define patients who most likely to respond to the drug.

http://feeds.sciencedaily.com/~r/sciencedaily/~3/eks-uq2Z7J0/130124183448.htm

Source: ScienceDaily Headlines - January 24, 2013 Category: Science Source Type: news

More News: Chronic Fatigue Syndrome | Food and Drug Administration (FDA) | Science